Presentation is loading. Please wait.

Presentation is loading. Please wait.

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

Published by Modified over 5 years ago

Similar presentations

Presentation on theme: "The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed."— Presentation transcript:

1 The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. Oligomerisation of the chimeric protein is the main proposed mechanisms for increased tumour cell survival and proliferation via the known pathways of Trk receptors. (A) NTRK1 gene with 17 exon sequences and respective TrkA protein regions.5 (B) Mechanism of entrectinib (E) action and the known mechanisms of acquired resistance (point mutation G595R and G567C) to E.50 Cys, cysteine clusters; Ig1 and Ig2, first and second immunoglobulin-like motifs, respectively; LRM, leucine-rich motifs; SP, signal peptide; TK, tyrosine kinase; TM, transmembrane. Alessio Amatu et al. ESMO Open 2016;1:e000023 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed."

Similar presentations

Neurotrophins & NTs Receptors Loredana Lombardi Ariadna Laguna Molecular Mechanisms of Development (EMBO), Barcelona 2006.

Neurotrophins & NTs Receptors Loredana Lombardi Ariadna Laguna Molecular Mechanisms of Development (EMBO), Barcelona 2006.
Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2):172-87. Krause DS, Van Etten RA N Engl J Med 2005;353(2):172-87.

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):
Samsung Genome Institute Samsung Medical Center

Samsung Genome Institute Samsung Medical Center
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Figure 1. Structure of the fly LGR2 gene and the corresponding cDNA sequence. A, Derivation of the fly LGR2 full-length cDNA from the genomic sequence.

Figure 1. Structure of the fly LGR2 gene and the corresponding cDNA sequence. A, Derivation of the fly LGR2 full-length cDNA from the genomic sequence.
Structure of the Gene for Congenital Nephrotic Syndrome of the Finnish Type (NPHS1) and Characterization of Mutations  Ulla Lenkkeri, Minna Männikkö,

Structure of the Gene for Congenital Nephrotic Syndrome of the Finnish Type (NPHS1) and Characterization of Mutations  Ulla Lenkkeri, Minna Männikkö,
TRKA oncogenic variants and TRK gene fusion partners.

TRKA oncogenic variants and TRK gene fusion partners.
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Anna F. Farago, MD, PhD, Long P

Anna F. Farago, MD, PhD, Long P
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,
Schematic representation of main EGFR-TKIs resistance mechanisms.

Schematic representation of main EGFR-TKIs resistance mechanisms.
Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.
(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Congenital Insensitivity to Pain with Anhidrosis: Novel Mutations in the TRKA (NTRK1) Gene Encoding A High-Affinity Receptor for Nerve Growth Factor 

Congenital Insensitivity to Pain with Anhidrosis: Novel Mutations in the TRKA (NTRK1) Gene Encoding A High-Affinity Receptor for Nerve Growth Factor 
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Similar presentations

Ads by Google